脊椎生技藥品市場－全球產業規模、佔有率、趨勢、機會及預測（按產品、手術、最終用戶、地區和競爭格局分類，2021-2031年）

全球脊椎生技藥品市場預計將從 2025 年的 38.8 億美元成長到 2031 年的 52.1 億美元，複合年成長率為 5.04%。

這個領域主要包括骨移植材料、骨形成蛋白和細胞基質等特殊生物材料，這些材料對於促進脊椎融合手術中的骨骼生長和癒合至關重要。推動這一成長的關鍵因素是全球人口老化導致退化性脊椎疾病風險增加，以及人們越來越傾向於微創手術技術，而微創手術則需要具有強骨誘導特性的藥物。美國脊椎註冊中心的數據證實了這個不斷成長的需求。數據顯示，預計到2024年，脊椎手術數量將比前一年增加17.86%，這將直接推動生物製藥的消耗。

儘管市場呈現正面勢頭，但高階生物製藥價格高昂以及醫保機構嚴格的報銷通訊協定仍構成重大障礙。外科醫生和醫院在幹細胞療法和生長因子等先進療法方面，往往面臨醫療覆蓋範圍不穩定的問題，並承受著選擇更經濟實惠的替代方案的經濟壓力。因此，這些經濟限制阻礙了新型、更昂貴的脊椎生物製藥的商業性化應用，有效減緩了高級產品在醫療保健領域的滲透速度。

市場促進因素

全球人口老化加劇，脊髓退化疾病的盛行率不斷上升，這是推動市場成長的主要因素。人口結構變化導致需要進行脊椎融合手術的病例數量增加，從而對能夠確保骨癒合困難患者成功實現骨融合的有效骨誘導劑產生了持續成長的需求。這一趨勢也體現在該行業強勁的財務業績中。例如，Orthofix Medical Inc. 在 2024 年 11 月公佈財報中顯示，其骨生長治療部門的淨銷售額增加了 9%。同樣，Stryker 公司截至 2024 年 10 月的會計年度業績顯示，其整形外科和脊椎部門的淨銷售額成長了 10.7%，這證實了手術量的健康復甦正在支撐整個行業的需求。

同時，合成骨移植材料的技術創新正在透過減少自體骨移植的需求來重新定義臨床實踐。外科醫生擴大選擇新一代骨移植材料，這些材料具有更優異的操作性和可預測的骨癒合效果，並避免了與傳統取骨手術相關的併發症風險。這種向先進基質的轉變正在推動旨在複製天然骨結構的產品迅速普及。例如，Kuros Biosciences公司在2024年8月報告稱，其專有骨移植材料MagnetOs的直接銷售額在上半年飆升了159%，這標誌著市場正發生重大轉變，轉向能夠提高手術效率的先進合成解決方案。

市場挑戰

由於高品質生物製品的高昂採購成本以及嚴格的報銷政策，該領域面臨許多挑戰。許多醫療機構營運資金捉襟見肘，難以證明購買昂貴的骨形成蛋白（BMP）和細胞基質的合理性，尤其是在有更經濟實惠的替代品（例如合成材料）可供選擇的情況下。因此，醫院採購部門為了確保財務永續性，往往會限制外科醫生使用這些高階產品，從而限制了此類先進產品類型的收入成長潛力。

主要支付方的支付率下降和政策變化加劇了這些財務挑戰。據北美脊椎協會 (NASS) 稱，美國醫療保險和醫療補助服務中心 (Medicare & Medicaid Services) 將 2024 年的醫生收費標準轉換係數降低了約 3.4%，這進一步加劇了複雜脊椎手術的經濟壓力。由於醫療服務提供者尋求降低每次手術的營運成本，這些報銷減少抑制了昂貴生物製藥的使用，從而阻礙了高階解決方案的普及，並推動市場轉向利潤率低的同質化產品。

市場趨勢

胜肽增強型骨誘導材料的出現正在改變市場格局。這類材料引入了模擬膠原蛋白細胞結合域的合成生物活性物質，從而促進骨骼修復。與存在安全隱患且高成本的傳統生長因子不同，這些基於胜肽的創新技術能夠直接刺激成骨細胞，為脊椎融合手術提供了一種標靶治療方法。其臨床療效正推動著監管部門的核准和商業性的成功。例如，2025年6月，Cerapedics公司宣布，其專有的PearlMatrix植入物的一項關鍵性研究表明，與自體移植相比，使用該植入物的患者在六個月時達到融合的比例是其兩倍以上，凸顯了這類新型生物製藥製劑的巨大潛力。

同時，新一代脫礦骨基質載體的進步正在滿足複雜手術中對改善移植骨固定和操作的迫切需求。製造商正從標準的糊狀和顆粒狀配方過渡到具有更優異吸收性和互連孔隙率的先進纖維基載體，從而確保微創手術中移植骨的穩定性。這項創新正在推動主要企業的顯著收入成長。 Bioventus公司報告稱，其外科解決方案部門2025年11月的淨銷售額達到5,020萬美元（年增9.3%），這一顯著成長主要歸功於先進骨移植替代物的廣泛應用。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球脊椎生技藥品市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品（脊椎同種異體移植、骨移植替代物、細胞基質）
  • 透過手術（頸椎前路椎間盤切除融合術（ACDF）、椎間椎間融合（TLIF）、腰椎後路椎間融合（PLIF）、腰椎前路椎間融合（ALIF）、腰椎側方椎間融合（LLIF））
  • 依最終用戶（醫院、門診機構）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美脊椎生技藥品市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲脊椎生技藥品市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區脊椎生技藥品市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲脊椎生技藥品市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲脊椎生技藥品市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球脊椎生技藥品市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Medtronic
• Stryker
• NuVasive
• Zimmer Biomet
• SeaSpine
• DePuy Synthes
• Orthofix
• Globus Medical
• RTI Surgical
• Baxter

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Spine Biologics Market is projected to expand from USD 3.88 Billion in 2025 to USD 5.21 Billion by 2031, reflecting a compound annual growth rate of 5.04%. This sector comprises a specialized range of biomaterials, such as bone grafts, bone morphogenetic proteins, and cell-based matrices, which are essential for promoting bone growth and healing during spinal fusion surgeries. The primary forces propelling this growth are the aging global population, which is increasingly prone to degenerative spinal conditions, and the growing preference for minimally invasive surgical techniques that require potent osteoinductive agents. Evidence of this expanding demand is highlighted by data from the American Spine Registry, which reported a 17.86% increase in spinal procedure volumes in 2024 compared to the previous year, directly driving consumption of these biological products.

Despite this positive momentum, the market encounters significant hurdles related to the high price of premium biological solutions and rigorous reimbursement protocols imposed by healthcare payers. Surgeons and hospitals often face inconsistent insurance coverage for advanced treatments like stem cell therapies and growth factors, creating financial pressure to select more affordable alternatives. Consequently, these economic constraints limit the widespread commercial adoption of newer, high-end spinal biologics, effectively slowing the penetration of premium products within the broader medical landscape.

Market Driver

The escalating prevalence of degenerative spinal disorders among an aging global population serves as a major engine for market growth. As demographic shifts lead to a higher incidence of conditions requiring spinal fusion, there is a sustained and increasing need for effective osteoinductive agents to ensure successful bone healing in compromised patients. This trend is evidenced by robust financial performance in the sector; for instance, Orthofix Medical Inc. reported a 9% increase in net sales for their Bone Growth Therapies segment in their November 2024 earnings release. Similarly, Stryker's October 2024 operating results showed a 10.7% rise in Orthopaedics and Spine net sales, underscoring a healthy recovery in procedural volumes that supports widespread industry demand.

Concurrently, technological innovation in synthetic scaffolds is redefining clinical practices by lessening the need for autografts. Surgeons are increasingly turning to next-generation bone grafts that provide superior handling characteristics and predictable fusion results without the morbidity risks associated with traditional bone harvesting. This transition toward advanced matrices is fueling rapid adoption of products designed to replicate natural bone structure. A prime example is Kuros Biosciences, which reported in August 2024 that direct sales of its MagnetOs bone graft surged by 159% in the first half of the year, demonstrating a significant market shift toward scientifically advanced synthetic solutions that improve surgical efficiency.

Market Challenge

The sector faces substantial obstacles due to the high acquisition costs of premium biological products coupled with stringent reimbursement policies. Healthcare institutions, often operating under tight financial constraints, frequently find it difficult to justify the expenditure required for expensive bone morphogenetic proteins or cell-based matrices when more affordable alternatives, such as synthetics, are available. As a result, hospital procurement teams often limit surgeon access to these high-end items to ensure financial sustainability, which in turn restricts the revenue growth potential for advanced product categories.

These financial challenges are intensified by reductions in payment rates and policy changes from major payers. According to the North American Spine Society, the Centers for Medicare & Medicaid Services enacted a nearly 3.4 percent reduction in the physician fee schedule conversion factor in 2024, creating a tougher economic landscape for complex spinal surgeries. Such cuts in reimbursement discourage the use of expensive biologics as providers attempt to lower overhead costs per procedure, ultimately dampening the adoption of premium solutions and steering the market toward commoditized, lower-margin options.

Market Trends

The market is being transformed by the emergence of peptide-enhanced osteoinductive materials, which introduce synthetic bioactive agents designed to mimic the cell-binding domains of collagen for accelerated bone repair. In contrast to traditional growth factors that may present safety concerns or high costs, these peptide-based innovations directly stimulate osteoblasts, providing a targeted approach for spinal fusion. This clinical efficacy is driving regulatory success and commercial validation; for example, Cerapedics Inc. announced in June 2025 that the pivotal study for its PearlMatrix graft showed it achieved fusion in over twice as many patients at six months compared to local autograft, highlighting the potent potential of this new biologics class.

Simultaneously, the evolution of next-generation demineralized bone matrix carriers is meeting the urgent need for better graft containment and handling during complex surgeries. Manufacturers are moving away from standard putty or particulate formulations toward advanced fiber-based carriers that offer superior wicking properties and interconnected porosity, ensuring graft stability during minimally invasive procedures. This innovation is generating significant revenue growth for key players; Bioventus Inc. reported in November 2025 that its Surgical Solutions segment achieved $50.2 million in net sales, a 9.3% increase attributed largely to the strong adoption of these advanced bone graft substitutes.

Key Market Players

• Medtronic
• Stryker
• NuVasive
• Zimmer Biomet
• SeaSpine
• DePuy Synthes
• Orthofix
• Globus Medical
• RTI Surgical
• Baxter

Report Scope

In this report, the Global Spine Biologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Spine Biologics Market, By Product

• Spinal Allografts
• Bone Graft Substitutes
• Cell-based Matrix

Spine Biologics Market, By Surgery

• Anterior Cervical Discectomy and Fusion (ACDF)
• Transforaminal Lumbar Interbody Fusion (TLIF)
• Posterior Lumbar Interbody Fusion (PLIF)
• Anterior Lumbar Interbody Fusion (ALIF)
• Lateral Lumbar Interbody Fusion (LLIF)

Spine Biologics Market, By End User

• Hospitals
• Outpatient Facilities

Spine Biologics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Spine Biologics Market.

Available Customizations:

Global Spine Biologics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Spine Biologics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Spinal Allografts, Bone Graft Substitutes, Cell-based Matrix)
  • 5.2.2. By Surgery (Anterior Cervical Discectomy and Fusion (ACDF), Transforaminal Lumbar Interbody Fusion (TLIF), Posterior Lumbar Interbody Fusion (PLIF), Anterior Lumbar Interbody Fusion (ALIF), Lateral Lumbar Interbody Fusion (LLIF))
  • 5.2.3. By End User (Hospitals, Outpatient Facilities)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Spine Biologics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Surgery
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Spine Biologics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Surgery
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Spine Biologics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Surgery
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Spine Biologics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Surgery
      • 6.3.3.2.3. By End User

7. Europe Spine Biologics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Surgery
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Spine Biologics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Surgery
      • 7.3.1.2.3. By End User
  • 7.3.2. France Spine Biologics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Surgery
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Spine Biologics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Surgery
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Spine Biologics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Surgery
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Spine Biologics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Surgery
      • 7.3.5.2.3. By End User

8. Asia Pacific Spine Biologics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Surgery
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Spine Biologics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Surgery
      • 8.3.1.2.3. By End User
  • 8.3.2. India Spine Biologics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Surgery
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Spine Biologics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Surgery
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Spine Biologics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Surgery
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Spine Biologics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Surgery
      • 8.3.5.2.3. By End User

9. Middle East & Africa Spine Biologics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Surgery
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Spine Biologics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Surgery
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Spine Biologics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Surgery
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Spine Biologics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Surgery
      • 9.3.3.2.3. By End User

10. South America Spine Biologics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Surgery
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Spine Biologics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Surgery
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Spine Biologics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Surgery
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Spine Biologics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Surgery
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Spine Biologics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Medtronic
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Stryker
• 15.3. NuVasive
• 15.4. Zimmer Biomet
• 15.5. SeaSpine
• 15.6. DePuy Synthes
• 15.7. Orthofix
• 15.8. Globus Medical
• 15.9. RTI Surgical
• 15.10. Baxter

16. Strategic Recommendations

17. About Us & Disclaimer